Grigg Ingham's 325 million euro acquisition of AML Therapeutics

July 15, Grigg Ingham announced the acquisition of a full stake in AML Therapeutics, a Swiss private company. AMAL Therapeutics, which specializes in cancer immunotherapy, is developing a range of first-of-its-kind therapeutic cancer vaccines based on its own technology platform, KISIMA.
AMAL's main vaccine product, ATP128, is currently being studied in patients with stage IV colorectal cancer and is expected to launch its first human trial later this month. Grigg Ingeham plans to combine the company's cancer immunization portfolio with AMAL's proprietary KISSIMA immune platform to develop new therapies.
The total value of the transaction is 325 million euros, including advance payments and future costs to meet clinical, development and regulatory milestones, as well as 100 million euros to be paid after certain business milestones are reached.
Bronger Ingeham's cancer immunology team is working to find immunoreactive therapies for non-inflammatory "cold" tumors, including a large number of incurable cancers that are often not cured with drugs such as immuno-checkpoint inhibitors. Immune targeting of cold tumors is a particular challenge. AMAL's KISSIMA vaccine technology is designed to stimulate a strong immune response. It will be a promising treatment option for patients with these types of cancer.
Before acquiring AMAL, Grigg Ingham acquired Vira-T Therapeutics in 2018 and obtained a license from OSE Immunotherapeutics for SIRP-α target antibodies. These initiatives have significantly strengthened Blainger Ingham's strategic focus in the field of immunocellular targeted therapy. By combining its world-class in-house research and development capabilities with the strengths of innovative biotech companies, Grigg Ingham is working to develop innovative immuno-oncology therapies while accelerating the development of next-generation cancer therapies.
Headquartered in the Faculty of Medicine of the University of Geneva and separately split from the University of Geneva in 2012, AMAL is currently supported by a consortium of corporate and institutional investors, with the Grigg Ingham Venture Fund and High-Tech Grunderfonds as initial seed investors, while VI Partners, Helsin Investment Fund, BioMed Partners and Schroder Adveq provide additional investments. AMAL's technology platforms and derivatives have received a wide range of patents and licenses. (Medical Rubik's Cube)